headerads

By clicking submit, you agree to the Disclaimer and consent to receive emails from us. ?php>

Thursday, November 1, 2012

Amarantus Biosciences Inc (OTC:AMBS) shares Soar 159% On Hefty Volume

AMARANTUS BIOSCIENCES
INC(OTC:AMBS) shares had an amazing run up in Thursday’s session and soared
158.54% to $0.0212 on hefty volume of 34.29 million shares – almost 6X its
average volume of 5.66 million shares.

Amarantus Biosciences is
a Biotechnology company that develops new diagnostics and treatment procedures
for Traumatic Brain Injury and Parkinson’s disease focusing on proprietary
anti-apoptosis protein MANF. The company announced that it plans on pursuing
the identification of one or multiple therapeutic indications for its MANF, its
lead therapeutic candidate, which could result in therapy receiving orphan drug
designations with the FDA (Food and Drug Administration).

The strategy is based
on exploiting MANF’s exclusive mechanism of action associated with proper
protein folding and processing in the endoplasmic reticulum so as to recognize
rare and/ or ultra rare ailments where MANF treatment procedures play an
important role in enhancing patient outcomes in disease states where no other
treatment alternatives are presently available.

CEO and President of
Amarantus, Gerald E. Commissiong said that protein misfolding and aggregation
plays an important role in a wide range of human ailments, taking into account
diseases like Alzheimer’s and Parkinson’s and also a number of rare and
ultra-rare diseases. He also said that MANF has a distinctive ability to intervene
in protein folding in an extracellular manner, making it potentially an ideal
biologic drug candidate for a wide variety of human conditions.

Parkinson’s still is
the primary focus of the company, especially in light of recently declared data
where MANF described superiority over GDNF in a neurostoration animal model of
Parkinson’s disease. The recent grant that the company was awarded with by the
Center of Excellence in Apoptosis Research will, however, let Amarantus’
scientific team to explore utility of MANF in diseases that have much smaller
patient populations. Amarantus wants to make a concerted effort to focus on
rare and ultra-rare diseases when reviewing the results. This strategy is
likely to show the company an accelerated pathway to commercialization by
recognizing therapeutic applications for MANF that would need a few clinical
trials. Data that has been already shared from databases available publicly
indicate that this orphan designation plan may turn out well for the company in
the near term.